Thanks to the introduction of new monoclonal antibodies and vaccines.
According to GlobalData, the respiratory syncytial virus (RSV) prevention market across eight major markets (8MM) is expected to reach US$620 million by 2030, growing at a CAGR of 26.7%.
The industry's expansion has been attributed to the introduction of new monoclonal antibodies (mAbs) and vaccines targeting maternal, adult and pediatric RSV cases.
Another six products currently in advanced stages of development are expected to be launched in 2030.
“In 2020, the only product marketed to prevent RSV was AstraZeneca/AbbVie's Synagis (palivizumab), a monoclonal antibody for use only in high-risk infants,” the report said. “
In the meantime, Synagis may be replaced by Beyfortus and clesrovimab for preventing RSV infection in infants, said GlobalData infectious disease analyst Anaelle Tannen.
Key opinion leaders highlighted several limitations of Synagis, including its short half-life, need for monthly dosing and high cost, which limit its clinical use despite its effectiveness in high-risk infants.
“While some unmet needs remain, the RSV prevention space will improve dramatically over the forecast period due to the influx of innovative new products,” Tannen said.
*8MM = United States, France, Germany, Italy, Spain, United Kingdom, Japan and Canada.
